8-KMaterial Agreements

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jul 17, 2008)

Filed July 17, 2008For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) reported on July 17, 2008, that its key collaboration partner, Novartis Institutes for BioMedical Research, Inc., has elected to extend their Research Collaboration and License Agreement for an additional year, now through October 12, 2009. This extension signifies continued confidence from Novartis in Alnylam's RNA interference (RNAi) technology and the potential therapeutic applications stemming from their joint efforts. The agreement, originally effective October 12, 2005, focuses on the discovery, development, and commercialization of RNAi-based therapeutics, with Novartis providing research funding, milestone payments, and future royalties. This extension provides Alnylam with continued financial support and validation of its platform technology. The agreement also includes provisions for Novartis to potentially integrate Alnylam's intellectual property into its operations under specific conditions, which would trigger additional payments to Alnylam. While the agreement allows for further extensions at Novartis's discretion, it also outlines termination clauses for both parties in case of material breaches, offering a degree of control and recourse.

Key Highlights

  • 1Novartis has extended the Research Collaboration and License Agreement with Alnylam Pharmaceuticals for one year, through October 12, 2009.
  • 2The collaboration focuses on the discovery, development, and commercialization of therapeutics based on RNA interference (RNAi) technology.
  • 3Novartis will continue to provide Alnylam with research funding and milestone payments.
  • 4The agreement includes provisions for Novartis to earn royalties on future net sales of products developed through the collaboration.
  • 5Novartis has a non-exclusive option to integrate Alnylam's RNAi intellectual property into its operations, subject to additional payments.
  • 6The agreement allows for further one-year extensions at Novartis's election.
  • 7Termination clauses exist for both parties in case of specified material breaches.

Frequently Asked Questions

The primary purpose of the agreement is to collaboratively discover, develop, and commercialize therapeutics based on Alnylam's RNA interference (RNAi) technology.

Alnylam receives research funding and milestone payments from Novartis. Additionally, Alnylam is entitled to royalties on the annual net sales of any products that result from this collaboration. There are also potential additional payments if Novartis exercises its option to integrate Alnylam's intellectual property.

The agreement has been extended for one year through October 12, 2009. Novartis has the option to further extend the agreement for an additional one-year term. This suggests continued commitment from Novartis to the collaboration.

Novartis has the right to extend the term of the agreement and a non-exclusive option to integrate Alnylam's RNAi intellectual property into its operations under specified circumstances, which would obligate Novartis to make additional payments.